Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Neil Grubert
#diabetes #insulin #subscription #oba
Independent Global Market Access Consultant, Trainer and Writer 18h An unusual outcomes-based subscription deal for insulin has just been announced by Eli Lilly and Prescryptive Health in the United States. The agreement will enable employers to offer employees “predictable, affordable, and transparent costs” for insulin in return for a flat, per-member, per-month subscription fee.
#uk #vpas #paybacks #rebates #launchsequencing
Independent Global Market Access Consultant, Trainer and Writer 3h Edited The UK market is likely to slip down the launch sequence list for many new medicines as a result of the rebates levied under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), according to a recent survey of members of the Ethical Medicines Interest Group (EMIG) regarding their investment plans for 2023. Many companies also intend to cut the supply of medicines to the UK.
#Spain #VALTERMED #RWE
How is Spain's VALTERMED online registry platform evolving, and what impact is it having on access to innovative medicines? Three years after its launch...
Neil Grubert on LinkedIn: #costcontainment #amnog #germany
Independent Global Market Access Consultant, Trainer and Writer 1w Edited The German Parliament has just approved a highly controversial #costcontainment package that could cost pharma nearly €3.7bn per year.
#nice #cdf #cancerdrugsfund
Independent Global Market Access Consultant, Trainer and Writer 6h What impact has the Cancer Drugs Fund (CDF) had on resolving uncertainty and securing long-term access for innovative oncology drugs?
The UK access environment has been transformed – what are the lessons for pharma and other countries? - Pf Media
SMART PROCUREMENT In recent years, NHS England has announced a growing stream of high-profile, clinically-led “smart deals” for medicines. However, awareness of what constitutes a “smart deal” is still not widespread. In Dark’s view, empathy is at the heart of smart procurement: the NHS and drug manufacturers have to understand each other’s needs and how they can be aligned. From the NHS’s perspective, the first requirement of smart procurement is to put the patient at the centre of deals.
The UK access environment has been transformed – and what are the lessons for Pharma and other countries? - Pf Media
ABOUT THE INTERVIEWEE Blake Dark is the Commercial Medicines Director for NHS England and Improvement (NHSEI). As the NHS’s chief negotiator with the pharmaceutical industry, he has developed the organisation’s capabilities to engage with companies and facilitate patient access to new treatments. He has oversight of national procurement and supply of hospital medicines through the Commercial Medicines Unit, arrangements for the Cancer Drugs Fund and the delivery of the Medicines Value Programme.
UK market access and the opportunities for pharma
The UK market access environment faces a time of change – the result of the convergence of several major drivers of reform. The COVID-19 pandemic will reinforce trends that were already taking place. The NHS in England is in the process of yet another fundamental reorganisation. Brexit has precipitated significant adjustments to the UK regulatory system. The National Institute for Health and Care Excellence (NICE) is poised to undergo an overhaul of its methods and processes.
Access Matters: The future for pharma
Over the last two decades, the growth of payer power has made access increasingly challenging for pharmaceutical companies. In our previous article, we considered how health technology assessment (HTA) and increasingly aggressive pricing methods have put drug manufacturers under pressure. In this article, we will examine how the pricing of one product in particular has been a catalyst for changes shaping the access environment of today and tomorrow.
Access Matters: The rise of the payer and implications for pharma
In a two-part series exclusive to Pharmafield, Neil Grubert and Mel Walker, Managing Director at Biopharma Futures, explore key trends in international market access. In this first instalment, they provide an overview of how payers approach access and the implications for pharma. Marketing authorisation is the key milestone in a drug’s lifecycle: without it, the product cannot be commercialised. Understandably, companies focus enormous effort on securing regulatory approval.
Access Matters: The rise of the payer and implications for pharma
In a two-part series exclusive to Pharmafield, Mel Walker, Managing Director at Biopharma Futures and Neil Grubert explore key trends in international market access. In this first instalment, they provide an overview of how payers approach access and the implications for pharma. Marketing authorisation is the key milestone in a drug’s lifecycle: without it, the product cannot be commercialised. Understandably, companies focus enormous effort on securing regulatory approval.
Market access in Europe: balancing access and affordability
European governments continue to pursue national agendas for market access, while also exploring opportunities to work together to achieve lower prices for new drugs Governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending.
Market access in Europe balancing access and affordability
European governments continue to pursue national agendas for market access, while also exploring opportunities to work together to achieve lower prices for new drugs Governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending.
Europe's market access outlook
Surveying Europe's market access landscape, the trend for cross-border collaboration looks set to continue, but there are significant changes ahead as some of the region's largest markets pursue their own agendas for market access reform. Driving this is the issue of pharmaceutical prices, criticism of which has reached unprecedented levels in the last couple of years, and one product in particular - Gilead's Sovaldi (sofosbuvir) - has been the main subject of scrutiny.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Neil
Contact Neil, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack